Supriya G. Mohile, MD, MS; Ronald M. Epstein, MD; Arti Hurria, MD; et al.
open access
JAMA Oncol. 2020;6(2):196-204. doi:10.1001/jamaoncol.2019.4728
This cluster-randomized clinical trial examines whether providing a geriatric assessment summary and geriatric assessment–guided recommendations to oncologists can improve communication about aging-related concerns.
-
Invited Commentary
Expanding the Scope of Geriatric Assessment for the Management of Cancer in Older Adults
Laura Biganzoli, MD; Amelia McCartney, MBBS; Nicolò Matteo Luca Battisti, MD
Safae Terrisse, MD; Eleni Karamouza, MSc; Chris C. Parker, MD; et al.
JAMA Oncol. 2020;6(2):206-216. doi:10.1001/jamaoncol.2019.4097
This meta-analysis of randomized clinical trials assesses overall survival in men with bone metastases from castration-resistant prostate cancer treated with bone-targeted radioisotopes and compares the effects of α-emitting with β-emitting radioisotopes.
Andrew J. Armstrong, MD, ScM; Mohammed Al-Adhami, PhD; Ping Lin, PhD; et al.
open access
JAMA Oncol. 2020;6(2):217-225. doi:10.1001/jamaoncol.2019.4636
This secondary analysis of the PREVAIL and AFFIRM randomized clinical trials examines the association between the detection of new unconfirmed lesions detected on follow-up bone scans and outcomes in enzalutamide-treated men with metastatic castration-resistant prostate cancer (mCRPC).
Keri L. Calkins, PhD; Geetanjali Chander, MD; Corinne E. Joshu, PhD; et al.
JAMA Oncol. 2020;6(2):227-235. doi:10.1001/jamaoncol.2019.4648
This cohort study assesses the association between cancer treatment and CD4 count and RNA levels in adults with human immunodeficiency virus.
Brian C. Baumann, MD; Nandita Mitra, PhD; Joanna G. Harton, MS; et al.
has active quiz
JAMA Oncol. 2020;6(2):237-246. doi:10.1001/jamaoncol.2019.4889
This comparative effectiveness study assesses whether proton therapy in the setting of concurrent chemoradiotherapy is associated with fewer 90-day unplanned hospitalizations or other adverse events and similar disease-free and overall survival compared with photon chemoradiotherapy among patients with nonmetastatic cancer.
Steven T. Bird, PhD, PharmD, MS; Fang Tian, PhD, MHS, MPH; Natasha Flowers, BA; et al.
JAMA Oncol. 2020;6(2):248-254. doi:10.1001/jamaoncol.2019.3994
This cohort study compares idelalisib treatment outcomes in the clinical setting among Medicare beneficiaries with outcomes in clinical trial data.
Yong Xia, MD; Jun Li, MD; Guanghua Liu, MD; et al.
JAMA Oncol. 2020;6(2):255-263. doi:10.1001/jamaoncol.2019.4477
This randomized clinical trial compares the long-term survival outcomes after repeat hepatectomy with those after percutaneous radiofrequency ablation among patients with recurrent hepatocellular carcinoma.
Elizabeth M. Cespedes Feliciano, ScD, SM; Wendy Y. Chen, MD; Valerie Lee, MHS; et al.
JAMA Oncol. 2020;6(2):264-270. doi:10.1001/jamaoncol.2019.4668
This cohort study evaluates the association between body composition and the risk of death based on the ratio of planned vs administered dose of chemotherapy in women with breast cancer.
Yihan He, PhD; Xinfeng Guo, PhD; Brian H. May, PhD; et al.
open access
JAMA Oncol. 2020;6(2):271-278. doi:10.1001/jamaoncol.2019.5233
This systematic review and meta-analysis provides an updated synthesis of the published randomized clinical trials into the use and advantages of acupuncture and/or acupressure among patients with cancer pain.
Jae Jeong Yang, PhD; Danxia Yu, PhD; Yong-Bing Xiang, MD; et al.
online only
JAMA Oncol. 2020;6(2):e194107. doi:10.1001/jamaoncol.2019.4107
This pooled analysis from 10 cohort studies that included more than 1.4 million participants evaluates whether an association exists between risk of lung cancer and the habitual consumption of dietary fiber (the main source of prebiotics) or yogurt (a probiotic food).